Pharming Group (ENXTAM:PHARM) - Cotización, noticias y análisis

Resumen de acción PHARM

Pharming Group N.V., empresa biofarmacéutica, desarrolla y comercializa terapias de sustitución de proteínas y medicamentos de precisión para el tratamiento de enfermedades raras en Estados Unidos, Europa y a escala internacional.

Acerca de la empresa

PHARM fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	4/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Cotiza un 81.1% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 52.89%

Los analistas coinciden en que el precio de las acciones subirá un 127%

Análisis de riesgos

Los accionistas han sido diluidos en el último año

Competidores de Pharming Group N.V.

Galapagos

ENXTAM:GLPG

€1.8b

Intercept Pharmaceuticals

NasdaqGS:ICPT

US$794.7m

TaiMed Biologics

TPEX:4147

NT$21.0b

PureTech Health

LSE:PRTC

UK£589.1m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Pharming Group
Historical stock prices
Current Share Price	€0.90
52 Week High	€1.31
52 Week Low	€0.86
Beta	0.73
1 Month Change	-10.80%
3 Month Change	-22.48%
1 Year Change	-11.94%
3 Year Change	-15.21%
5 Year Change	9.52%
Change since IPO	-99.05%

Noticias y actualizaciones recientes

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Feb 14

Recent updates

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Feb 14

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Nov 11

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Aug 23

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Jun 20

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Mar 16

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Feb 17

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

Dec 08

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Aug 05

Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

Mar 21

These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Mar 19

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Feb 20

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price

Oct 29

Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly

Jun 03

Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM)

May 12

Is Pharming Group N.V.'s (AMS:PHARM) Recent Performance Tethered To Its Attractive Financial Prospects?

Mar 15

Pharming Group (AMS:PHARM) Seems To Use Debt Rather Sparingly

Feb 15

Rentabilidad de los accionistas

	PHARM	NL Biotechs	Mercado NL
7D	2.2%	-0.6%	-0.1%
1Y	-11.9%	-11.7%	16.2%

Rentabilidad vs. Industria: PHARM igualó al sector Dutch Biotechs , que obtuvo un rendimiento del -11.7% el año pasado.

Rentabilidad vs. Mercado: PHARM obtuvo unos resultados inferiores a los del mercado Dutch, que fue del 18% el año pasado.

Volatilidad de los precios

Is PHARM's price volatile compared to industry and market?
PHARM volatility
PHARM Average Weekly Movement	4.8%
Biotechs Industry Average Movement	7.1%
Market Average Movement	3.6%
10% most volatile stocks in NL Market	7.9%
10% least volatile stocks in NL Market	2.2%

Precio estable de las acciones: El precio de las acciones de PHARM ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de PHARM (5%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1988	382	Simon de Vries	www.pharming.com

Pharming Group N.V., empresa biofarmacéutica, desarrolla y comercializa terapias de sustitución proteica y medicamentos de precisión para el tratamiento de enfermedades raras en Estados Unidos, Europa y a escala internacional. La empresa ofrece RUCONEST, un inhibidor recombinante de la C1 esterasa para el tratamiento de ataques agudos en pacientes adultos y adolescentes con angioedema hereditario agudo (AEH); y Joenja (leniolisib), un inhibidor oral de PI3K? de molécula pequeña para el tratamiento del síndrome de fosfoinositido 3-cinasa delta activada.

Resumen de fundamentos de Pharming Group N.V.

¿Cómo se comparan los beneficios e ingresos de Pharming Group con su capitalización de mercado?
Estadísticas fundamentales de PHARM
Capitalización bursátil	€606.09m
Beneficios(TTM)	-€9.86m
Ingresos (TTM)	€229.32m

2.6x

Ratio precio-ventas (PS)

-61.5x

Ratio precio-beneficio (PE)

¿Está PHARM sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de PHARM
Ingresos	US$245.32m
Coste de los ingresos	US$25.21m
Beneficio bruto	US$220.10m
Otros gastos	US$230.65m
Beneficios	-US$10.55m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

May 08, 2024

Beneficios por acción (BPA)	-0.016
Margen bruto	89.72%
Margen de beneficio neto	-4.30%
Ratio deuda/patrimonio	63.3%

¿Cómo se ha desempeñado PHARM a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción PHARM

Recompensas

Análisis de riesgos

Competidores de Pharming Group N.V.

ENXTAM:GLPG

€1.8b

NasdaqGS:ICPT

US$794.7m

TPEX:4147

NT$21.0b

LSE:PRTC

UK£589.1m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Pharming Group N.V. announced that it expects to receive €100 million in funding

Price target increased by 11% to €2.00

Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Consensus estimates of losses per share improve by 31%

Recent updates

Pharming Group N.V. announced that it expects to receive €100 million in funding

Price target increased by 11% to €2.00

Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Consensus estimates of losses per share improve by 31%

Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Consensus EPS estimates upgraded to US$0.014 loss, revenue downgraded

Consensus estimates of losses per share improve by 34%

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: US$0.005 (vs US$0.014 in 3Q 2022)

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 140%

Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan

First half 2023 earnings released: US$0.017 loss per share (vs US$0.03 profit in 1H 2022)

Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer

Now 20% undervalued

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor

Investor sentiment improves as stock rises 15%

Price target increased by 8.9% to €1.83

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: US$0.021 (vs US$0.025 in FY 2021)

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V. Provides Update on EMA Regulatory Review of Leniolisib for Apds in Europe

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Now 20% undervalued

Now 20% undervalued

Investor sentiment improved over the past week

Pharming Group N.V. Announces Positive Interim Analysis Data from Open-Label Extension Study of Leniolisib in Presentation At the 64Th American Society of Hematology (ASH) Annual Meeting and Exposition

Pharming Group N.V. to Report Fiscal Year 2022 Results on Mar 16, 2023

Pharming Group N.V. Announces Positive Results of Phase 3 Clinical Trial of Investigational Drug Leniolisib

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

High number of new directors

Investor sentiment improved over the past week

Pharming Group N.V. Announces European Medicines Agency Validates its Marketing Authorisation Application Under Accelerated Assessment for Leniolisib

Third quarter 2022 earnings: EPS exceeds analyst expectations

Pharming Group N.V. Submits Marketing Authorisation Application to European Medicines Agency for Leniolisib

Price target increased to €13.52

Pharming Group N.V. Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

Second quarter 2022 earnings released: EPS: US$0.025 (vs US$0.009 in 2Q 2021)

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

Pharming Group N.V. Receives Accelerated Assessment in Europe for Leniolisib for the Treatment of Rare Immunodeficiency, APDS

Consensus forecasts updated

First quarter 2022 earnings: EPS misses analyst expectations

GIMV NV (ENXTBR:GIMB) completed the acquisition of 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM).

High number of new directors

Pharming Receives Agreement of Paediatric Investigation Plan and Promising Innovative Medicine Designation for Leniolisib from UK MHRA

GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for ?6.9 million.

Pharming Group N.V. Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting

Consensus revenue estimates fall by 14%

Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to €1.80

Is Pharming Group (AMS:PHARM) Using Too Much Debt?